Incannex Healthcare Limited
Incannex Healthcare Limited
- Market cap
- $22.25M
Your view on IXHL
Overview
What the company does, where it operates, and who runs it.
About Incannex Healthcare Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joel Bradley Latham
- Headquarters
- 207/11 Solent Circuit, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joel Bradley Latham
- Headquarters
- 207/11 Solent Circuit, Sydney, NSW, AU
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name.
The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases.
It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion.
The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Incannex Healthcare Limited. Starting points for Incannex Healthcare Limited: EPS -$0.66, beta 2.84 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Incannex Healthcare Limited. Trailing twelve-month EPS for Incannex Healthcare Limited stands at -$0.66. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterMar 2027 | Next quarterSep 2027 | This yearYear to Jun 2015 | Next yearYear to Jun 2021 |
|---|---|---|---|---|
| Average estimate | −$0.49 | −$0.57 | $11.31 | $11.31 |
| Lowest estimate | −$0.49 | −$0.57 | $11.31 | $11.31 |
| Highest estimate | −$0.49 | −$0.57 | $11.31 | $11.31 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | −$0.571 | −$0.60 | — | — |
| Growth vs a year ago | — | +5.8% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterMar 2027 | Next quarterSep 2027 | This yearYear to Jun 2015 | Next yearYear to Jun 2021 |
|---|---|---|---|---|
| Average estimate | $30.00M | $0.00 | $92.49M | $92.49M |
| Lowest estimate | $30.00M | $0.00 | $92.49M | $92.49M |
| Highest estimate | $30.00M | $0.00 | $92.49M | $92.49M |
| Number of analysts | 1 | 0 | 1 | 1 |
| A year ago | $86.00 | $0.00 | — | — |
| Growth vs a year ago | +34883620.9% | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Incannex Healthcare Limited. Incannex Healthcare Limited has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AGENAgenus Inc. | Healthcare | Biotechnology | $270.1M | ||
| CGTXCognition Therapeutics, Inc. | Healthcare | Biotechnology | $55.4M | ||
| IRDOpus Genetics, Inc. | Healthcare | Biotechnology | $332.0M | ||
| LUCDLucid Diagnostics Inc. | Healthcare | Medical - Devices | $72.6M | ||
| SCLXScilex Holding Company | Healthcare | Drug Manufacturers - General | $4.0M | ||
| SEERSeer, Inc. | Healthcare | Biotechnology | $75.9M | ||
| STSSSharps Technology, Inc. | Healthcare | Medical - Instruments & Supplies | $53.7M | ||
| SXTCChina SXT Pharmaceuticals, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $14,124 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NOX.AXNoxopharm Limited | Healthcare | ASX | — | ||
| NRIXNurix Therapeutics, Inc. | Healthcare | NASDAQ | $1.4B | ||
| NRSNNeuroSense Therapeutics Ltd. | Healthcare | NASDAQ | $2.4M | ||
| NRSNWNeuroSense Therapeutics Ltd. | Healthcare | NASDAQ | $120,867 | ||
| NRX.VNurExone Biologic Inc. | Healthcare | TSXV | — | ||
| NRXBFNurExone Biologic Inc. | Healthcare | OTC | — | ||
| NRXPNRx Pharmaceuticals, Inc. | Healthcare | NASDAQ | $95.3M | ||
| NRXSNeurAxis, Inc. | Healthcare | AMEX | $59.9M | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| NSHS.CNNanoSphere Health Sciences Inc. | Healthcare | CNQ | $256,880 | ||
| NSHSFNanoSphere Health Sciences Inc. | Healthcare | OTC | $102,752 | ||
| NTHINeonc Technologies Holdings, Inc. | Healthcare | NASDAQ | $90.9M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| PSILAdvisorShares Psychedelics ETF | $42M in assets | 0.80% | |
Largest holders first, then the funds most concentrated in IXHL.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Incannex Healthcare Limited, and how their positions are changing. At a $22.3M market value, institutional positions materially move Incannex Healthcare Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Incannex Healthcare Limited executives and directors. Shares of Incannex Healthcare Limited have traded between $0.08 and $2.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Incannex Healthcare Limited. Coverage tracks Incannex Healthcare Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Incannex Healthcare Limited.